Monoclonal antibody and other Fc-containing molecules can be constructed using the disclosed variations in the Fc region causing increased resistance to host and pathogen derived proteases and exhibiting the ability to interact with Feγ receptors and initiate complement directed cytotoxicity as demonstrated by functional assays. The Fc-containing molecules are useful in the treatment of various diseases and disorders wherein FcR-driven host functions contribute activity.
